Odaia Pitch Deck: All 15 Slides + Teardown

Introduction

Odaia’s Series B deck is a prime example of how to pitch a vertical AI solution to a sophisticated investor audience. In an era where 'AI' is often used as a vague buzzword, Odaia grounds its technology in the very specific, high-value problem of pharmaceutical commercialization. By focusing on the MAPTUAL platform, the company demonstrates a clear understanding of the 'Life of Pharma Commercial Teams' and the friction points that prevent life-saving therapies from reaching patients efficiently.

Slide 1: Title and Leadership

The deck opens with a professional headshot of Philip Poulidis, identified as the CEO of ODAIA. While simple, this puts a face to the leadership immediately, which is particularly important in the Series B stage where the ability of the CEO to scale the organization is a primary concern for investors.

Slide 2: Mission and Vision

Slide 2 defines the company's purpose. The Mission is stated as 'Reducing patients’ time to therapy by facilitating meaningful interactions with healthcare providers, through human-centric software powered by AI.' The Vision expands this to 'Guiding humans to improved health journeys through our collective experiences.' This slide is crucial because it frames the business not just as a data tool, but as a critical link in the healthcare delivery chain. It connects technical output (AI) to human outcomes (time to therapy).

Slide 3: The Experienced Team

This is one of the strongest slides in the deck. It lists five key executives with deep, relevant experience:

Philip Poulidis (CEO): Startup founder with multiple exits and experience as a tech executive for $B divisions. · Helen Kontozopoulos (Chief Tech Evangelist): Adjunct Professor at the University of Toronto and founder of a startup incubator. · Eric Trépanier (CCO): 25+ years in life sciences, a Doctor of Pharmacy, and a senior executive in data-driven healthcare. · Zak Beharie (CTO): 20+ years in the tech industry, architecting B2B SaaS platforms. · Mark Zou (CPO): 15+ years of product design experience across banking and life sciences.

The inclusion of a Doctor of Pharmacy as the Chief Commercial Officer provides immediate credibility that the company understands the regulatory and clinical nuances of the pharma industry.

Slide 4: Transforming the Status Quo

Slide 4 uses a classic 'Problem vs. Solution' table. It identifies that Pharma Commercial Teams are Inefficient due to:

Labor intensive manual processes. · Time-consuming workflows. · Limited insights due to the work involved. · Insights that are outdated when deployed.

It counters these with the MAPTUAL Solution : consistent data, rapid onboarding, reproducible output, and real-time predictive insights. This slide clearly articulates the 'pain' and the 'aspirin.'

Slide 5: The Life of Pharma Commercial Teams

This slide dives deeper into the workflow. It highlights that ODAIA provides a 'No-Code Method' for creating business objectives. This is a key selling point for enterprise software, as it implies that the marketing and sales teams—not just the data scientists—can use the tool. It mentions objectives like 'New drug launch preparation' and 'Defend and Grow Share,' showing that the platform is useful in both offensive and defensive market positions.

Slide 6: Predictive Analytics & Insights Platform

Slide 6 serves as the product overview. It uses a series of verbs to describe the platform's utility: Integrates (multiple data sources), Predicts (physician & patient journeys), Automates (targeting & prioritization), Simplifies (pre-call planning), Measures (omnichannel attribution), and Delivers (predictive forecasting). A tablet mockup shows the UI, suggesting the product is mature and ready for field use.

Slide 7: Lifecycle Support

This slide addresses the Total Addressable Market (TAM) within a single client. By showing that MAPTUAL helps across Launch Product , Established Product , and New Indication , Odaia proves that their software isn't a one-time tool for a launch, but a long-term infrastructure play. The comparison between 'Without MAPTUAL' (relying on expensive, slow consultants) and 'With MAPTUAL' (leveraging existing data for real-time agility) hits on the cost-saving and speed-to-market benefits that drive Series B valuations.

Slide 8: Closing

The final slide is a simple 'Thank You' featuring the ODAIA and MAPTUAL logos. While standard, it maintains the clean, professional branding seen throughout the deck.

What Works in the Odaia Deck

1. Extreme Vertical Focus: Odaia does not try to be an AI tool for everyone. Every slide is drenched in the language of the pharmaceutical industry ('HCP targeting,' 'time to therapy,' 'new indication'). This specificity builds trust with specialized investors.

2. The 'No-Code' Value Prop: In the enterprise space, adoption is the biggest hurdle. By explicitly stating they offer a 'No-Code Method' on Slide 5, they address the fear that the software will be too complex for the actual sales reps and marketers to use.

3. Team Pedigree: For a $25M round, investors need to know the team can handle enterprise-grade scale. The combination of a CEO with multiple exits and a CCO who is a Doctor of Pharmacy is a powerful 'founder-market fit' signal.

What is Missing from the Odaia Deck

1. Hard Metrics and Traction: The public version of this deck contains no mention of Annual Recurring Revenue (ARR), growth rates, or Net Revenue Retention (NRR). While these may have been in a supplemental data room, their absence in the main narrative makes it harder to judge the business's actual momentum.

2. Case Studies and Logos: Slide 7 talks about 'Brands,' but no specific pharmaceutical companies are named. Seeing logos of Top 20 Pharma companies would significantly de-risk the investment in the eyes of a Series B lead.

3. The Competitive Landscape: The deck assumes a vacuum or a competition against 'manual processes.' In reality, there are other AI-driven life science analytics platforms. A slide addressing why Odaia wins against other tech incumbents would be beneficial.

4. The Ask: There is no slide detailing how much is being raised or how the capital will be deployed (e.g., R&D, international expansion, sales team hiring). We know from publisher facts that they raised $25M, but the deck itself doesn't state the goal.

Founder Takeaways

Focus on the 'Before and After': If you are building vertical SaaS, your best friend is the 'Status Quo' slide. Odaia’s Slide 4 and Slide 7 do an excellent job of making the current way of doing business look archaic and expensive.

Sell the Outcome, Not the Tech: Notice that 'AI' is mentioned, but the focus is on 'Time to Therapy' and 'Commercial Objectives.' Founders should lead with the business result and use the technology as the 'how,' not the 'why.'

Leverage Domain Experts: If your industry is highly regulated (like healthcare or finance), ensure your team slide highlights people with the relevant degrees and decades of experience. It proves you won't make 'rookie' regulatory mistakes.